Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO NASDAQ:CGEM NASDAQ:CRON NASDAQ:MGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.98+1.5%$1.88$0.51▼$2.66$265.76M0.421.02 million shs201,111 shsCGEMCullinan Therapeutics$17.61+2.3%$16.26$5.68▼$19.43$1.08B-0.01887,170 shs243,981 shsCRONCronos Group$2.91+1.6%$2.76$1.92▼$3.43$1.08B0.891.30 million shs608,321 shsMGTXMeiraGTx$11.97+3.0%$11.36$6.62▼$15.35$1.11B1.2726,872 shs223,691 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-2.26%-3.71%-11.59%+14.41%+235.34%CGEMCullinan Therapeutics-1.49%-2.49%-6.57%+31.88%+106.35%CRONCronos Group+0.35%+2.88%+0.35%+7.12%+42.29%MGTXMeiraGTx-1.69%-4.44%-7.34%+26.03%+43.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.98+1.5%$1.88$0.51▼$2.66$265.76M0.421.02 million shs201,111 shsCGEMCullinan Therapeutics$17.61+2.3%$16.26$5.68▼$19.43$1.08B-0.01887,170 shs243,981 shsCRONCronos Group$2.91+1.6%$2.76$1.92▼$3.43$1.08B0.891.30 million shs608,321 shsMGTXMeiraGTx$11.97+3.0%$11.36$6.62▼$15.35$1.11B1.2726,872 shs223,691 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-2.26%-3.71%-11.59%+14.41%+235.34%CGEMCullinan Therapeutics-1.49%-2.49%-6.57%+31.88%+106.35%CRONCronos Group+0.35%+2.88%+0.35%+7.12%+42.29%MGTXMeiraGTx-1.69%-4.44%-7.34%+26.03%+43.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.67Moderate Buy$4.60132.91% UpsideCGEMCullinan Therapeutics 2.63Moderate Buy$32.1482.58% UpsideCRONCronos Group 2.20Hold$2.30-20.83% DownsideMGTXMeiraGTx 2.75Moderate Buy$26.00117.21% UpsideCurrent Analyst Ratings BreakdownLatest ALXO, MGTX, CGEM, and CRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $39.007/17/2026MGTXMeiraGTx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/8/2026CGEMCullinan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/8/2026MGTXMeiraGTx Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$25.00 ➝ $26.007/8/2026MGTXMeiraGTx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.006/26/2026ALXOALX Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/11/2026CGEMCullinan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$37.006/8/2026CGEMCullinan Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.005/29/2026CRONCronos Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/26/2026MGTXMeiraGTx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/19/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.00(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$0.48 per shareN/ACGEMCullinan TherapeuticsN/AN/AN/AN/A$6.92 per shareN/ACRONCronos Group$146.59M7.39$0.01 per share227.33$3.00 per share0.97MGTXMeiraGTx$81.39M13.62N/AN/A($0.07) per share-171.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$101.69M-$1.49N/AN/AN/AN/A-124.06%-85.57%8/11/2026 (Estimated)CGEMCullinan Therapeutics-$219.88M-$3.36N/AN/AN/AN/A-51.45%-47.64%8/6/2026 (Estimated)CRONCronos Group-$9.45M$0.01290.79N/AN/A-1.14%-1.26%-1.20%8/6/2026 (Estimated)MGTXMeiraGTx-$114.20M-$1.48N/AN/AN/A-151.12%N/A-54.96%8/13/2026 (Estimated)Latest ALXO, MGTX, CGEM, and CRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026MGTXMeiraGTx-$0.3286N/AN/AN/A$0.70 millionN/A8/11/2026Q2 2026ALXOALX Oncology-$0.15N/AN/AN/AN/AN/A8/6/2026Q2 2026CGEMCullinan Therapeutics-$0.7993N/AN/AN/A$3.67 millionN/A8/6/2026Q2 2026CRONCronos Group$0.01N/AN/AN/A$44.20 millionN/A5/14/2026Q1 2026MGTXMeiraGTx-$0.6060-$0.57+$0.0360-$0.57$17.00 million$0.29 million5/11/2026Q1 2026CRONCronos Group$0.01$0.01N/A$0.04$42.20 million$45.21 million5/8/2026Q1 2026ALXOALX Oncology-$0.15-$0.17-$0.02-$0.17N/AN/A5/7/2026Q1 2026CGEMCullinan Therapeutics-$0.8359-$0.75+$0.0859-$0.75$3.67 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.027.217.21CGEMCullinan TherapeuticsN/A10.2810.28CRONCronos GroupN/A21.8720.73MGTXMeiraGTxN/A0.550.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%CGEMCullinan Therapeutics86.31%CRONCronos Group8.71%MGTXMeiraGTx67.48%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%CGEMCullinan Therapeutics8.60%CRONCronos Group7.80%MGTXMeiraGTx7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology40134.56 million106.31 millionOptionableCGEMCullinan Therapeutics3061.46 million56.17 millionOptionableCRONCronos Group450373.03 million343.94 millionOptionableMGTXMeiraGTx30092.61 million85.76 millionOptionableALXO, MGTX, CGEM, and CRON HeadlinesRecent News About These CompaniesSome Potential Merit Within MeiraGTx Holdings2 hours ago | seekingalpha.comRichard Giroux Sells 56,000 Shares of MeiraGTx (NASDAQ:MGTX) StockJuly 29 at 4:37 AM | insidertrades.comMeiraGTx (NASDAQ:MGTX) CFO Richard Giroux Sells 56,000 SharesJuly 28 at 12:06 PM | marketbeat.comRubric Capital Management LP Acquires 824,669 Shares of MeiraGTx Holdings PLC $MGTXJuly 28 at 6:55 AM | marketbeat.comMeiraGTx (NASDAQ:MGTX) Stock Price Up 7.9% - Here's WhyJuly 27 at 12:39 PM | marketbeat.comMeiraGTx Holdings PLC (NASDAQ:MGTX) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 19, 2026 | marketbeat.comWall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?July 15, 2026 | zacks.comAnalysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX) and Vera Therapeutics (VERA)July 12, 2026 | theglobeandmail.comWhat This MeiraGTx Insider Sale Might Mean With Two Drug Filings NearJuly 12, 2026 | fool.comHC Wainwright Has Positive Forecast for MeiraGTx Q3 EarningsJuly 10, 2026 | marketbeat.comHC Wainwright Issues Positive Forecast for MeiraGTx EarningsJuly 9, 2026 | marketbeat.comMeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?July 8, 2026 | zacks.comMeiraGTx (NASDAQ:MGTX) Insider Sells 27,659 SharesJuly 8, 2026 | insidertrades.comMeiraGTx wins $400M investment from Oberland CapitalJuly 7, 2026 | msn.comMeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)July 7, 2026 | globenewswire.comMeiraGTx (NASDAQ:MGTX) Hits New 52-Week High - Time to Buy?July 6, 2026 | marketbeat.comMeiraGTx: The Market Is Missing The Manufacturing PivotJune 29, 2026 | seekingalpha.comWhat Could MeiraGTx’s Latest Equity Award Reveal About Long-Term Alignment?June 16, 2026 | kalkinemedia.comKMeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 5, 2026 | seekingalpha.comMeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 - SlideshowJune 5, 2026 | seekingalpha.comCan MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a HintMay 20, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALXO, MGTX, CGEM, and CRON Company DescriptionsALX Oncology NASDAQ:ALXO$1.98 +0.03 (+1.54%) As of 03:06 PM Eastern This is a fair market value price provided by Massive. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Cullinan Therapeutics NASDAQ:CGEM$17.60 +0.40 (+2.30%) As of 03:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Cronos Group NASDAQ:CRON$2.90 +0.05 (+1.57%) As of 03:06 PM Eastern This is a fair market value price provided by Massive. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.MeiraGTx NASDAQ:MGTX$11.97 +0.35 (+3.01%) As of 03:06 PM Eastern This is a fair market value price provided by Massive. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Just Flipped the AI Spending Narrative Overnight Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling? Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes Tesla: After a Rough Quarter, 2 Very Different Futures Come Into Focus Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending Powering Up: NextEra and Brookfield Build an Off-Grid Empire 2 Unique Space ETFs That Could Upend the Industry DoorDash's Drone Certification Could Reshape Its Delivery Margins Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
